CA-RESMED
1.9.2020 15:02:05 CEST | Business Wire | Press release
ResMed (NYSE: RMD, ASX: RMD) announced today the launch of its AirTouch N20 nasal mask, the company’s first CPAP nasal mask with a memory foam cushion and softest nasal mask ever.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200901005249/en/
AirTouch N20 uses the same patented UltraSoft memory foam cushion as the full face AirTouch F20 mask introduced in 2017. Both adapt to the curves and contours of each face, creating a soft, personalized fit designed to increase comfort and CPAP adherence. In a clinical study, 90 percent of CPAP users gave the UltraSoft foam cushion a high rating for comfort – a 4 or 5 out of 5.1
This unique comfort also comes with added convenience: The foam cushion doesn’t require cleaning when replaced on an appropriate schedule.
Most important, AirTouch N20’s comfort and convenience can help increase patient satisfaction, adherence, and benefit from long-term therapy.
Additional features include:
- Quick-release elbow allows patients to easily disconnect from tubing without removing their mask, and magnetic clips guide the headgear to the frame quickly and easily
- AirFit N20’s mask frame fits both AirFit N20 silicone and AirTouch N20 memory foam cushions, allowing clinicians to conveniently switch between the two during fittings or send patients home with both to see which cushion type they prefer
- A seal designed for therapy pressures up to 30 cm H2 O
“CPAP therapy should be simple, comfortable, and easy to use – and AirTouch N20 delivers on all three,” said Jim Hollingshead, ResMed president of Sleep and Respiratory Care. “The foam cushion is uniquely comfortable, adapts to give everyone a personalized fit, and doesn’t need cleaning. It’s ideal for nasal CPAP users and their providers.”
AirTouch N20 is the latest in ResMed’s family of innovative CPAP masks, connected devices, and digital health technologies for helping millions with sleep apnea, COPD, and other chronic diseases sleep, breathe, and live better.
AirTouch N20 is now available in the U.S., Canada, and most of Europe, with Asia-Pacific launches planned for later this year. For more information, visit ResMed.com/AirTouchN20 .
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
1 ResMed clinical study: ResMed AirTouch F20 full face mask evaluation of facial marks. A total of 29 evaluable CPAP users trialed the mask at home for 30 nights in place of their current mask in which they were experiencing facial marks. Conducted from September 11, 2017 to February 19, 2018. (AirTouch N20 uses the same UltraSoft™ memory foam cushion technology as AirTouch F20).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901005249/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BioLife to Showcase Oral Peptide Delivery Technology During London Life Sciences Week3.11.2026 16:03:00 CET | Press release
Company to highlight granted patent portfolio, preclinical semaglutide data and potential applications across future peptide medicines at LSX Investival BioLife Products Limited today announced its participation in London Life Sciences Week, where it will highlight its patented oral peptide delivery technology and recent advances in its intellectual property portfolio. BioLife will present at the LSX Investival Showcase on Monday, November 16, 2026, from 3:15 to 3:30 p.m. GMT, at Old Billingsgate, London. The presentation will be led by Former US Ambassador James P. Cain, Strategic Advisor to the Chairman & Founder, alongside Ludivine Delattre, Business and Corporate Relations, and will highlight the scientific journey behind the technology and its potential applications. BioLife is focused on developing a novel approach to delivering peptide therapeutics orally. Built on over 35 years of pharmaceutical effervescence expertise and two decades of oral peptide research by founder and inv
Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan3.11.2026 16:00:00 CET | Press release
Five-year agreement builds on Sceye’s successful stratospheric connectivity tests in Japan and advances full-scale deployment of HAPS as stratospheric infrastructure and a key pillar of SoftBank’s strategy for a Ubiquitous Network Sceye, a U.S. aerospace and material science company building High Altitude Platform Systems (HAPS) for stratospheric infrastructure, today announced a five-year Master Services Agreement (MSA) with SoftBank Corp. (TOKYO:9434, “SoftBank”) to manufacture, launch, and operate a fleet of Sceye’s HAPS over Japan with the aim of achieving nationwide coverage. This agreement advances the companies’ partnership from flight demonstrations toward full-scale stratospheric infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103391128/en/ Sceye and SoftBank Corp. Sign Agreement for Fleet of Stratospheric Platforms Targeting Nationwide Coverage in Japan Sceye’s HAPS will form a key pillar of SoftB
Organigram to Acquire Aurora andEstablish a Global Cannabis Leader3.11.2026 15:16:00 CET | Press release
Organigram to acquire Aurora for C$7.80 per Aurora Common Share; Aurora shareholders will have the option to receive such Consideration in cash, Organigram shares or a combination of both, subject to proration. Transaction provides Aurora shareholders with certainty of value, meaningful immediate liquidity and participation in the combined entity Offer represents a 93% premium to Aurora’s Unaffected Share Price on August 10, 20261 and a 21% premium to the implied value of the unsolicited Curaleaf Hostile Bid as of November 2, 20262, unanimously rejected by Aurora’s Board of Directors Organigram shareholders to participate alongside Aurora shareholders in a company with greater scale, enhanced supply chain certainty, global footprint and diversification The combined company will own and operate five EU-GMP certified production and distribution facilities and bring world-class innovation to existing and new markets to meet international demand and support global market share expansion Th
Individual AI Productivity Soars but Organizational Impact Stalls3.11.2026 15:00:00 CET | Press release
Company-wide gains blocked by tool fragmentation and governance gaps; while workers continue to feel the strain of single-player AI and negative impact on wellbeing Miro®, the collaboration and context layer for the AI era, today released research exploring how AI is changing individual productivity and team performance. The survey of over 9,500 leaders and workers finds that while 83% of people believe that AI has improved their individual productivity at work, only 56% say that the quality of output has improved as a result of AI deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103271772/en/ Knowledge workers are individually more capable than ever with the majority now well beyond the ‘foundational stage’ of AI understanding and deployment - according to the Miro report‘The State of Intelligent Collaboration’. But enterprise fragmentation caused by operational silos, misalignment, and AI governance challenges
CoStar Group Opens Nominations for Its Sixth Annual CoStar Impact Awards3.11.2026 15:00:00 CET | Press release
The CoStar Impact Awards Celebrate Influential Commercial Property Projects and Transactions Across 129 Markets in the United Kingdom, the United States and Canada CoStar Group (NASDAQ: CSGP), a leading provider of online real estate marketplaces, information, analytics and digital twins in the property markets, has opened nominations for the sixth annual CoStar Impact Awards. The CoStar Impact Awards celebrate commercial property projects and transactions that have made a significant impact in neighbourhoods or submarkets across 129 major international markets in the United Kingdom, the United States and Canada. The awards will recognize outstanding projects and transactions completed in 2026, as selected by a panel of sector professionals representing each respective market. Judges panels comprised of commercial property industry professionals will select winners from each market in the United Kingdom based on the following categories: Lease of the Year, Commercial Development of the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
